Streetbeat News

Products Services

WINT

Windtree Therapeutics announced positive topline results from its Phase 2B SEISMiC extension study of Istaroxime in early cardiogenic shock. The study showed significant improvements in systolic blood pressure over six hours and notable secondary endpoint improvements.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:10 pm

BTCUSD

Bill Maher criticizes Bitcoin mining for its high energy consumption, claiming it undermines green energy progress. He compares its environmental impact to adding millions of gas-powered cars. The debate on crypto's carbon footprint is intensifying.

Portfolio Pulse from Murtuza Merchant

September 25, 2024 | 12:10 pm

AVDL

Avadel Pharmaceuticals published data in 'Sleep Medicine' showing the efficacy of LUMRYZ in improving narcolepsy symptoms, regardless of alerting agent use. The Phase 3 REST-ON trial confirmed significant improvements in wakefulness and reduced cataplexy episodes.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:10 pm

ERAS

Erasca, Inc. (NASDAQ:ERAS) will present preliminary Phase 1 data for naporafenib plus trametinib in RAS Q61X mutant solid tumors at the 36th EORTC-NCI-AACR Symposium. The company is also conducting a Phase 3 trial in NRAS-mutant melanoma. A virtual R&D update for investors is scheduled for October 24, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:09 pm

AIMD

Ainos has received IRB approval from National Taiwan University Hospital for a clinical trial of its FDA-designated orphan drug VELDONA, targeting HIV-related oral warts. The company is awaiting Taiwan FDA approval to commence the trial.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:09 pm

PALI

Palisade Bio is progressing towards the launch of a Phase 1 clinical study for its lead program, PALI-2108, aimed at treating ulcerative colitis. The company has completed necessary preclinical studies and is on track to initiate clinical site and dosing by year-end.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:08 pm

TCMD

Tactile Systems Technology, Inc. (NASDAQ:TCMD) announced positive results from a clinical trial using their Flexitouch device for lymphedema treatment. The study showed significant improvements in limb girth, cellulitis events, and skin hyperpigmentation over 52 weeks.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:07 pm

HRTX

Heron Therapeutics' stock is rising following the FDA's approval of its Prior Approval Supplement application for the ZYNRELEF vial access needle.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:07 pm

HRTX

Heron Therapeutics has received FDA approval for its Prior Approval Supplement Application for the ZYNRELEF Vial Access Needle, which could enhance the product's marketability and usage.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:06 pm

CDTX

Cidara Therapeutics will present safety and pharmacokinetic data on its influenza drug-Fc conjugate, CD388, at the 2024 OPTIONS XII conference.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:05 pm